Abbvie

This study follows about 700 adults with advanced diffuse large B-cell lymphoma or follicular lymphoma who are receiving epcoritamab as part of their routine care. Researchers will track how well the drug works in real-world settings over up to 3 years. The goal is to see how man…

This study tests an experimental eye injection called AGN-193408 SR in people with open-angle glaucoma or high eye pressure. The goal is to see if it safely lowers pressure inside the eye, which can prevent vision loss. About 96 adults who have had cataract surgery at least 4 mon…

This study tests a new combination of drugs (telisotuzumab adizutecan, budigalimab, and standard chemotherapies) as a first treatment for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. About 180 adults will receive…

This study tracks about 678 adults with moderate to severe rheumatoid arthritis across 80 German clinics to see how long they stay on upadacitinib versus TNF inhibitors. The goal is to compare treatment retention rates in everyday practice, not in a controlled lab setting. Partic…

This study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it can control the disease as well as standard monthly eye injections, but with a single treatment. About 714 adults aged …

This study tests an experimental drug called ABBV-142 for idiopathic pulmonary fibrosis (IPF), a rare lung disease that causes scarring and makes breathing hard. About 165 adults with IPF will receive either ABBV-142 or a placebo for 52 weeks to see if it safely slows lung functi…

This study tests a combination of two drugs, venetoclax and azacitidine, in about 100 adults in India with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for standard intensive chemotherapy. The goal is to see how well the treatment controls the cancer an…

This study tests four targeted medicines (risankizumab, trosunilimab, lutikizumab, and ABBV-8736) in about 540 adults with moderate to severe Crohn's disease. The goal is to see if these drugs can reduce gut inflammation and improve symptoms better than current treatments. Partic…

This study tests if the drug atogepant can safely prevent chronic migraines in teenagers aged 12 to 17. About 420 teens will take either atogepant or a placebo daily for 12 weeks. The goal is to see if the drug reduces the number of migraine days and is safe for this age group.

This program provides early access to venetoclax, a targeted therapy for several blood cancers including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma. It is for people who have no other suitable treatments and cannot join a clinical trial…

This early-stage study tests an experimental drug called ABBV-969 in men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals are to check the drug's safety, find the best dose, and see if it can lower PSA levels. About 230 p…

This study tests a drug called venetoclax in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to other treatments. About 110 participants will receive the drug to see if it shrinks their cancer. The goal is to…

This study tests whether the drug atogepant can prevent menstrual migraines—headaches that strike around your period. About 430 women with regular cycles and a history of migraine will take either atogepant or a placebo pill daily for 3 menstrual cycles. The goal is to see if the…

This program offers early access to an investigational drug called telisotuzumab adizutecan for people with solid tumors who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefits outweigh the risks. Availability …

This study tests an experimental drug called etentamig (ABBV-383) in adults with multiple myeloma that has returned or not improved after prior treatments. The goal is to find the best dose and check for side effects. About 210 participants will receive the drug by IV infusion ov…

This program offers early access to ABBV-706, an investigational drug for small cell lung cancer, before it is officially approved. It is for people who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefits outwe…

This study tests an experimental oral medication, upadacitinib, in children aged 1 to 18 with active systemic juvenile idiopathic arthritis (sJIA), a rare and serious form of childhood arthritis that can affect the whole body. About 90 participants will receive either upadacitini…

This study tests how well the drug Foslevodopa/Foscarbidopa works for people in the early advanced stages of Parkinson's disease. About 125 adults in Germany will receive the drug as a continuous infusion under the skin for up to 12 months. The goal is to see if it improves motor…

This study tests whether upadacitinib, a daily pill, can help adults with moderate to severe eczema (atopic dermatitis) who did not get enough relief from dupilumab injections. About 200 participants will receive upadacitinib or continue dupilumab for 32 weeks. The main goal is t…

This study tests two medicines, upadacitinib and dupilumab, in children aged 2 to 12 with moderate to severe eczema that isn't controlled by creams. About 675 kids worldwide will take one of the drugs for up to 160 weeks. The goal is to see which works better at clearing the rash…

This study tests whether a new combination of two experimental drugs (livmoniplimab and budigalimab) plus chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with untreated metastatic non-squamous non-small cell lung cancer. …

This study tests a gene therapy called ABBV-RGX-314 for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. About 561 adults aged 50 and older will receive either a single gene therapy injection or standard anti-VEGF shots as needed. The goal …

This study tests an experimental drug, etentamig, for adults with multiple myeloma, a blood cancer that often returns or resists treatment. About 440 participants worldwide will receive etentamig alone or combined with other cancer drugs to find safe doses and check if it shrinks…

This study tests two drugs, risankizumab and lutikizumab, alone or together, in 120 adults with active psoriatic arthritis (PsA). PsA causes painful, swollen joints. The goal is to see if these treatments reduce symptoms like joint pain and swelling. Participants will be randomly…

This study tests the drug risankizumab in children aged 2 to 17 with moderate to severe ulcerative colitis, a condition that causes inflammation and bleeding in the colon. The goal is to see how well the drug works and how safe it is over time. Participants will receive the drug …

This study is testing the drug upadacitinib (a daily pill) in 352 adults with axial spondyloarthritis, a type of arthritis that causes chronic back pain and stiffness. The goal is to see how well the drug controls disease activity and pain in real-world settings over 52 weeks. Pa…

This study tests a new drug, ABBV-706, combined with atezolizumab against standard treatment for people with extensive-stage small cell lung cancer that hasn't been treated yet. About 180 adults will receive either the new combination or standard care to find the best dose and se…

This study tests a new drug, telisotuzumab adizutecan, combined with the approved drug osimertinib for people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell). The goal is to see if the combination works better than standard treatment (osime…

This study tests an experimental drug, etentamig (ABBV-383), in about 76 adults with AL amyloidosis, a rare disease where abnormal proteins build up in organs. The drug aims to reduce these proteins by targeting the bone marrow cells that produce them. Participants receive the dr…

This study follows about 1,200 adults with psoriatic arthritis to see how long they stay on risankizumab compared to other advanced treatments. Psoriatic arthritis causes joint pain and swelling due to an overactive immune system. Participants will take their prescribed medicatio…

This study is testing a material called ARTIA, used to support breast implants during reconstruction after mastectomy. About 783 adults who need immediate two-stage breast reconstruction will receive either ARTIA or standard care. The goal is to see if ARTIA reduces major complic…

This study compares an experimental drug, telisotuzumab vedotin, to a standard chemotherapy (docetaxel) in adults with a specific type of advanced non-small cell lung cancer that has already been treated. The cancer must have high levels of a protein called c-Met. About 698 parti…

This study tests an experimental drug called mirvetuximab soravtansine (MIRV) combined with either bevacizumab or carboplatin in people with a specific type of ovarian cancer. About 320 participants will receive different doses to find the safest and most effective treatment. The…

This study follows 240 Japanese adults with moderate to severe Crohn's disease who are prescribed upadacitinib, an approved drug. Researchers will track side effects and how well the drug controls symptoms over 64 weeks in real-world settings. The goal is to confirm safety and ef…

This early-stage study tests a new drug called ABBV-295 in 96 adults with obesity. Participants receive multiple injections of the drug or a placebo to check for side effects, how the drug moves through the body, and any weight changes. The goal is to gather safety information be…

This study tests a drug called mirvetuximab soravtansine (MIRV) in people with a type of ovarian cancer that no longer responds to platinum chemotherapy. The drug targets a protein (FRα) on cancer cells to deliver a cell-killing agent. About 110 participants will receive MIRV on …

This study tracks 250 adults with moderate-to-severe Crohn's disease who are switching to a second treatment (upadacitinib or risankizumab) after their first therapy stopped working well. Researchers will see if these drugs help patients achieve remission without needing steroids…

This study looks at how well a drug called Foslevodopa/Foscarbidopa works for people with advanced Parkinson's disease in everyday medical practice in Belgium. About 120 adults will receive the drug as a continuous injection under the skin, as prescribed by their doctor, and be f…

This study tests an experimental drug called telisotuzumab vedotin in adults with a specific type of advanced lung cancer (non-small cell lung cancer that has a high level of a protein called c-Met). About 150 participants will be randomly assigned to one of three different dose …

This study tests a new medicine called ABBV-6628 for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 66 adults aged 50 and older will receive eye injections of the study drug or an approved treatment to check…

This study tests an investigational drug called MEDI0618 to see if it can safely reduce the number of migraine headache days in adults with episodic migraine. About 488 participants will receive either the drug or a placebo as a shot under the skin. The main goal is to compare ho…

This early-stage study tests a new drug, ABBV-291, in adults with Non-Hodgkin's lymphoma that has returned or not responded to treatment. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 165 participants will receive the drug throu…

This study tests different schedules for starting the drug venetoclax, given with either obinutuzumab or acalabrutinib, in people with untreated chronic lymphocytic leukemia (CLL). The main goal is to find the safest way to ramp up the dose to prevent a serious side effect called…

This early-stage study tests an experimental drug, ABBV-711, alone or with another drug (budigalimab) in about 220 adults with advanced squamous tumors (like certain lung or head/neck cancers) that have not responded to standard treatments. The goal is to see if the drug is safe …

This study tests if a daily pill called ubrogepant can prevent migraines that happen around a woman's period. About 496 women with menstrual migraines will take the pill or a placebo for 7 days each cycle. The goal is to see if it reduces the number of migraine days and is safe t…

This study tests a new drug called IMGN151 for people with gynecologic cancers, including ovarian cancer. The goal is to see if it is safe and works well, either alone or with other cancer treatments. About 377 adults will take part across 50 sites worldwide. Participants will ge…

This early-stage study tests an experimental drug called ABBV-319 in adults with B-cell cancers (lymphomas and leukemia) that have come back or not responded to treatment. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 154 parti…

This program offers early access to telisotuzumab vedotin, an investigational drug for non-small cell lung cancer, before it is officially approved. It is for patients who have no other suitable treatment options and cannot join ongoing clinical trials. A doctor must decide if th…

This study tests an experimental drug called telisotuzumab adizutecan combined with standard chemotherapy drugs (FOLFOX or 5FU/LV) and either bevacizumab or panitumumab in people with metastatic colorectal cancer (cancer that has spread). The goal is to find the best dose that is…

This program offers early access to upadacitinib for people with Crohn's disease, ulcerative colitis, certain types of arthritis, or atopic dermatitis who have no other good treatment options and cannot join a clinical trial. A doctor must decide if the potential benefits outweig…

This study tests an investigational drug called ABBV-CLS-628 in adults with autosomal dominant polycystic kidney disease (ADPKD), a genetic condition that causes fluid-filled cysts to grow in the kidneys. About 240 participants will receive either the drug or a placebo by IV ever…

This study follows about 270 Italian adults with advanced Parkinson's disease who are already prescribed Foslevodopa/Foscarbidopa by their doctor. Researchers will track changes in quality of life and caregiver well-being over 12 months under routine care. The goal is to see how …

This study tests if Armour Thyroid, a natural thyroid extract, works as well as the standard synthetic T4 medication for adults with hypothyroidism (underactive thyroid). About 2,800 people currently stable on synthetic T4 will switch to Armour Thyroid or stay on their current dr…

This study tests a drug called risankizumab in children aged 2 to 18 with moderate to severe Crohn's disease. The goal is to see if it can reduce gut inflammation and improve symptoms like belly pain and diarrhea. Participants will receive the medicine through an IV or injection …

This study compares two approved drugs, risankizumab and vedolizumab, to see which works better for adults with moderate to severe ulcerative colitis who have not used targeted therapies before. About 530 participants will receive one of the two medications and be monitored for s…

This early-stage trial tests an investigational drug called ABBV-319 in about 36 adults with lupus or Sjogren's disease. The drug works by depleting certain immune cells (B cells) that are overactive in these conditions. The main goals are to check the drug's safety, how it moves…

This early-stage study tests an experimental drug called ABBV-438 in about 127 adults whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink the cancer. Partic…

This study tests a new drug combination (etentamig plus iberdomide) in adults whose multiple myeloma has returned or stopped responding to treatment. The goal is to find safe doses and see how well the combo controls the cancer. About 135 participants will be enrolled worldwide.

This study tests whether adding mirvetuximab soravtansine to standard maintenance therapy (bevacizumab) can delay cancer regrowth in people with a specific type of ovarian, fallopian tube, or peritoneal cancer. Participants must have cancer that responded to initial platinum-base…

This study tests whether the drug upadacitinib can safely help regrow hair in people with severe alopecia areata, an autoimmune condition causing patchy or total hair loss. About 123 adults and teens in Japan with at least 25% scalp hair loss will take either the drug or a placeb…

This study tests three new treatments for adults with moderate to severe rheumatoid arthritis (RA) who have not improved with at least one prior therapy. Participants will receive either a single drug (lutikizumab or ravagalimab), a combination of both, or a placebo. The goal is …

This program offers early access to elezanumab, an investigational drug, for people with acute spinal cord injury who have no other suitable treatment options and cannot join ongoing clinical trials. A doctor must decide if the potential benefit outweighs the risks. The drug is n…

This study tests whether giving a second course of the drugs venetoclax and obinutuzumab can control chronic lymphocytic leukemia (CLL) that has come back after initial treatment. About 75 adults who previously responded to a similar drug combination will receive up to 24 cycles …

This study tests whether atogepant, a drug already approved for adults, can safely prevent migraines in children aged 6 to 17. About 450 participants will take a daily tablet (low-dose, high-dose, or placebo) for 12 weeks. The goal is to reduce the number of migraine days each mo…

This study tests a new drug, telisotuzumab adizutecan, combined with an immunotherapy (PD-1 inhibitor) for people with advanced non-squamous lung cancer who haven't had prior treatment. The goal is to find the safest and most effective dose. About 252 adults will take part across…

This study tests an oral medication called upadacitinib in children aged 2 to 18 with moderate-to-severe Crohn's disease who haven't improved with other treatments. The goal is to see if the drug can reduce gut inflammation and improve symptoms like abdominal pain and diarrhea. P…

This study looks at how well risankizumab works for adults with moderate to severe ulcerative colitis in everyday medical practice. About 200 participants will receive the drug as prescribed by their doctor and be followed for up to 52 weeks. The main goal is to see if symptoms l…

This study tests whether a new drug called etentamig, given with daratumumab, works better than the current standard treatment for adults newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. About 660 participants worldwide will receive either on…

This study tests an experimental drug, telisotuzumab adizutecan, in people aged 12 and older whose solid tumors have a specific genetic change called MET amplification. The goal is to see if the drug can shrink tumors and to check for side effects. Participants receive the drug t…

This study tests a daily pill called venetoclax in about 14 Japanese adults whose Waldenström macroglobulinemia (a rare blood cancer) has returned or stopped responding to prior treatment. The goal is to see if the drug can shrink the cancer or slow its growth. Participants take …

This study tests a new drug, telisotuzumab adizutecan, against standard care in about 140 adults with colorectal cancer who have completed initial treatment but still have cancer DNA in their blood (ctDNA positive) with no visible tumors on scans. The goal is to see if the new dr…

This study tests a gel stent device to lower eye pressure in people with glaucoma, a leading cause of blindness. About 130 adults aged 45 and older will get the stent placed either inside or outside the eye. Researchers will check safety and how well it reduces eye pressure over …

This study tests a new drug, telisotuzumab adizutecan, against standard care for people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer) that has worsened after taking a modern targeted therapy. About 430 adults will take part. T…

This study looks at how well the drug upadacitinib (RINVOQ) controls symptoms of ulcerative colitis, a condition causing inflammation and bleeding in the colon. About 400 adults in Germany, Austria, and Switzerland who are already prescribed the drug will be followed for up to 2 …

This early-stage study tests an experimental drug called ABBV-324 in about 232 adults with liver cancer (hepatocellular cancer) or a type of lung cancer (squamous non-small cell lung cancer). The main goals are to check safety and see if the drug shrinks tumors. Participants rece…

This early-phase study tests an experimental drug called ABBV-525 in about 150 adults with B-cell blood cancers (like certain lymphomas and leukemias). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants take the drug by mouth …

This study will follow about 1000 teens and adults in China with moderate to severe atopic dermatitis (eczema) who are prescribed upadacitinib by their doctor. The goal is to see how the drug is used in real-world settings, including dose changes and how well patients stick to th…

This study tests an oral drug called upadacitinib for people with severe alopecia areata, a condition where the immune system attacks hair follicles, causing hair loss. About 1,500 adults and teens will take either the drug or a placebo daily for up to 160 weeks. The goal is to s…

This study follows about 80 Chinese adults with moderate to severe ulcerative colitis who are already prescribed upadacitinib by their doctor. Researchers will track how well the drug controls symptoms like bloody diarrhea over one year, using only routine checkup data. The goal …

This study tests a new drug, surzetoclax (ABBV-453), in adults with multiple myeloma that has returned or stopped responding to prior treatments. The drug is given alone or combined with standard myeloma therapies to find the safest and most effective dose. About 130 participants…

This study tests a new drug combination (carboplatin and mirvetuximab soravtansine) given before surgery to people with advanced ovarian, fallopian tube, or peritoneal cancer that has a specific protein (FRα). The goal is to see if the treatment shrinks tumors enough to improve s…

This study tests a new drug called etentamig against standard treatments for adults with multiple myeloma that has returned or stopped responding. About 380 participants will receive either etentamig or a standard therapy chosen by their doctor. The goal is to see if etentamig ca…

This early-stage study is testing a new drug called ABBV-901 for women with advanced ovarian cancer that has stopped responding to standard platinum chemotherapy. Researchers will give the drug alone and in combination with an existing cancer therapy (bevacizumab) to about 207 pa…

This study is testing whether a daily pill called upadacitinib can help control moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition. It's for about 1,300 teens and adults whose HS didn't improve enough with previous strong medications. Participants will tak…

This study follows 200 adults in Japan with moderate to severe ulcerative colitis who are already prescribed the approved drug risankizumab by their doctors. Researchers will track how well the medication controls their bowel disease symptoms in real-world settings over three yea…

This study follows 1000 adults with migraine who are already prescribed atogepant by their doctors. It aims to see how effective the medication is at preventing migraine attacks in real-world, everyday use over two years. Researchers will track whether participants feel their mig…

This is an early-stage safety study testing a new drug called azirkitug, both alone and in combination with other cancer therapies. It aims to find safe doses and understand how the drug moves through the body in adults with advanced solid tumors like lung, head and neck, and sev…

This study is monitoring the long-term safety and effectiveness of the XEN45 implant, a tiny device placed in the eye to lower pressure. It is comparing the implant to a standard glaucoma surgery (trabeculectomy) in about 130 adults in China who have open-angle glaucoma. The main…

This study is testing whether a new drug called risankizumab is safe and effective for treating juvenile psoriatic arthritis, a condition where the immune system attacks joints and skin. About 40 children worldwide will receive either risankizumab or an approved drug called adali…

This study is testing whether a new drug called Icalcaprant can help control depressive episodes in adults with bipolar I or II disorder. About 195 participants will take either the drug or a placebo pill daily for six weeks, while continuing their current mood stabilizer medicat…

This study is checking the safety and effectiveness of atogepant, a drug already approved for migraine prevention, in Korean adults. About 3000 people with chronic or episodic migraines will take the drug as prescribed by their doctor and be followed for up to 12 weeks. The goal …

This study looks at how to reduce eye problems caused by the drug mirvetuximab soravtansine in people with recurrent ovarian cancer. About 100 participants will receive the drug and be monitored for eye side effects, with some using special eye drops to try to prevent them. The g…

This study tests a new artificial tear, ABBV-444, against a standard brand (Refresh Optive) in 250 adults with dry eye disease. Participants use the assigned eye drops for 90 days. The goal is to see if the new formula improves eye comfort and surface health better than the exist…

This study tests an experimental drug called icalcaprant in adults with major depressive disorder who are currently having a depressive episode. About 195 participants will take either the drug or a placebo daily for 6 weeks. The goal is to see if the drug safely reduces depressi…

This study tests an experimental drug called ABBV-932 for adults with generalized anxiety disorder (GAD) who still have symptoms despite taking antidepressants. About 315 participants will receive either ABBV-932 or a placebo alongside their current medication for 6 weeks. The go…

This study follows 700 adults with moderate-to-severe plaque psoriasis who are already prescribed risankizumab by their doctor. Researchers will measure how the drug impacts quality of life, including skin symptoms and daily functioning, over up to 2.5 years. The goal is to see h…

This study tests whether cariprazine, already approved for adults, can safely ease depressive episodes in children and teens aged 10-17 with bipolar I disorder. About 380 participants will receive either the drug or a placebo for 6 weeks, with dose adjustments based on response. …

This study compares a new hyaluronic acid filler called NOA VOLUME to the well-known JUVÉDERM VOLUMA XC for restoring lost volume in the mid-face (cheek area). About 231 adults with moderate to severe volume loss will receive injections and be followed for up to 31 months. The go…

This study looks at whether a continuous infusion of Foslevodopa/Foscarbidopa, given under the skin, can improve sleep disturbances in adults with advanced Parkinson's disease. About 103 participants in Spain will be followed for up to 12 weeks as they receive the treatment as pa…

This early-stage study tests a new drug called ABBV-295 in 24 healthy Japanese adults who are overweight or obese. The main goal is to check the drug's safety and how the body processes it. Participants receive injections, and researchers monitor for side effects. This is a first…

This study looks at whether taking ubrogepant, a migraine medication, during the earliest phase of a migraine (called the prodrome) can prevent moderate to severe headache. About 189 adults with 4–10 migraine days per month will take the drug as prescribed and report their sympto…

This study tests whether ubrogepant, a drug already approved for adults, can safely and effectively treat migraine headaches in children and adolescents aged 6 to 17. About 1,059 participants will receive either the drug or a placebo during a single migraine attack. The main goal…

This study is testing a new drug called ABBV-932 to see if it is safe and tolerable for people with bipolar I or II disorder who are currently having a depressive episode. About 200 adults will take the drug as capsules for 26 weeks, with regular check-ups and questionnaires. The…

This study tests an experimental drug called emraclidine in about 268 adults with schizophrenia. The goal is to see if it safely reduces symptoms like hallucinations and confused thinking compared to a placebo. Participants take the drug or placebo as pills for up to 6 weeks, wit…

This program provides early access to the investigational drug tavapadon for people with Parkinson's disease who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefits outweigh the risks. The drug is not yet appro…

This study tests an investigational drug called AGN-151607-DP (gemibotulinumtoxinA) to see if it can help close the belly wall after open ventral hernia surgery without needing a complex additional procedure. About 200 adults with a midline ventral hernia will receive either the …

This study tests an injectable gel called ELAPR002f for adults with moderate to severe indented acne scars on both cheeks. About 395 participants will receive either the gel or a saline placebo over 2 months and be followed for a year. The goal is to see if the gel safely reduces…

This study tests whether atogepant, a drug already approved to prevent migraines, can also stop a migraine attack quickly once it starts. About 1,300 adults with a history of migraines will take either atogepant or a placebo at the start of a migraine and report if their pain goe…

This study tests an investigational drug called lutikizumab for people with moderate to severe hidradenitis suppurativa (HS), a chronic skin disease causing painful lumps and scars. About 1,280 adults and teens will receive either lutikizumab or a placebo for 16 weeks, then all w…

This study tests an investigational drug called eluxadoline in children aged 6 to 17 who have irritable bowel syndrome with diarrhea (IBS-D). The goal is to see if the drug can improve stool consistency and reduce symptoms safely. About 95 children will take either the drug or a …

This study looks at how a new drug, ABBV-722, changes the way the body processes five common medicines. It involves 12 healthy adults who will take ABBV-722 along with a mix of other drugs to measure safety and drug levels. The goal is to understand potential interactions, not to…

This early-stage study tests a new drug, ABBV-547, in healthy adults to see if it is safe and how the body handles it. About 87 people in the US and Japan will receive a single dose of the drug or a placebo. The main goal is to check for side effects and measure drug levels in th…

This study follows about 1,884 pregnant women with migraines to see if taking Ubrelvy or Qulipta affects the baby's health. Researchers will compare mothers who took one of these drugs to those who did not. The goal is to learn about birth defects, miscarriage, and infant health …

This early-stage study tests the safety and tolerability of emraclidine, an experimental oral drug, in 32 healthy adults aged 65 and older. Participants receive either the drug or a placebo to see how the drug moves through the body and whether it causes side effects. This study …

This study looks at how a new drug called ABBV-722 changes the way birth control pills work in the body. It involves 16 healthy volunteers who will take both the drug and the pill. The goal is to see if the drug affects the levels of the pill's hormones, which could change how we…

This early-stage study is testing a new drug called ABBV-243 in healthy adults to see if it is safe and how the body processes it. About 66 participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure drug levels in the blood. …

This study follows 500 people with chronic lymphocytic leukemia (CLL) who are taking venetoclax alone or with other drugs as part of their normal treatment. Researchers will track how well the cancer responds, side effects, and costs. The goal is to see how the drug performs outs…

This study looks back at medical records of 2,000 people with hepatitis C who took an 8-week course of the drug combination Glecaprevir/Pibrentasvir. The goal is to see how safe and effective the treatment is for those also taking prescription or illegal drugs. No new treatments …

This study looks at how doctors actually use a 'treat-to-target' approach for people with Crohn's disease or ulcerative colitis. Researchers will review medical records of 2000 adults over 24 months to see if adjusting treatment based on regular check-ups leads to better outcomes…

This study aims to understand how alopecia areata, vitiligo, and hidradenitis suppurativa affect the daily lives and well-being of nearly 2,800 teens and adults across multiple countries. Researchers will use questionnaires and skin assessments to measure symptom severity and qua…

This early-stage study tests how two drugs, ABBV-722 and upadacitinib, affect each other in the body when taken together by healthy adults. Researchers will measure drug levels in the blood and watch for any side effects. The goal is to gather safety and interaction data, not to …

This is the very first study testing a new oral drug called ABBV-1042 in people. It will check for side effects and see how the drug moves through the body in 48 healthy adults. The main goal is to determine if the drug is safe and well-tolerated at different dose levels.